Countering weapons of mass destruction is “an enduring mission of the U.S. Armed forces,” the US Army said last week in a new doctrinal publication.
Counter-WMD operations are defined as actions taken “against actors of concern to curtail the research, development, possession, proliferation, use, and effects of WMD, related expertise, materials, technologies, and means of delivery.”
See Combined Arms Countering Weapons of Mass Destruction, ATP 3-90.40, June 29, 2017.
The Army document does not refer to any specific countries such as North Korea.
Instead, it says generally that “Conventional forces and SOF [special operations forces] capabilities may be necessary to stop the movement of CBRN materials, WMD components and means of delivery, WMD-related personnel, or functional weapons into or out of specified areas or nations. Such actions may require boarding vessels and using search and detection capabilities to secure and seize shipments.”
Counter-WMD activities are directed not only at the weapons themselves but at the networks that produce, sponsor, fund and utilize them.
“Interacting with and engaging networks requires the use of lethal and nonlethal means to support, influence, or neutralize network members, cells, or an entire network. As part of this effort, commanders select, prioritize, and match effective means of interacting with friendly networks, influencing the neutral network, and neutralizing threat networks,” the new Army publication said.
“Commanders and staff utilize the targeting process to identify targets, determine the desired effects on those targets, predict secondary and tertiary effects, and plan lethal and nonlethal effects. This process enables the prosecution of targets to capitalize on and exploit targets of opportunity.”
Nuclear weapons budgeting is like agreeing to buying a house without knowing the sales price, the mortgage rate, or the monthly payment.
Employing a living approach to evidence synthesis, disseminated at a national level, is a streamlined way to enable evidence-based decision-making nationwide.
By providing essential funding mechanisms, the Bioeconomy Finance Program will reduce the risks inherent in biotechnology innovation, encouraging more private sector investment.
While the U.S. has made significant advancements and remained a global leader in biotechnology over the past decade, the next four years will be critical in determining whether it can sustain that leadership.